How To Improve Post-Approval Evidence Generation
Early Scientific Advice Can Flag Up Likely Evidence Gaps
Executive Summary
A new scientific paper explains how companies can improve their post-licensing evidence generation plans by seeking scientific advice from EU regulators and health technology bodies at appropriate times during the drug development process.